Also from this source

You just read:

Amicus Therapeutics Announces FDA Agreement to Commence Phase 2 Study of AT2220 Co-administered with Enzyme Replacement Therapy for Pompe Disease

News provided by

Amicus Therapeutics

Mar 08, 2011, 07:00 EST